Pinteon Therapeutics

Pinteon Therapeutics, founded in 2014 and headquartered in Newton, Massachusetts, is dedicated to developing innovative therapeutics aimed at slowing brain degeneration and preserving cognitive function. The company focuses on targeting Pin1, a central regulator involved in various diseases, including cancer, central nervous system disorders, and autoimmune conditions. By inhibiting or activating Pin1, Pinteon seeks to interrupt the spread of toxic tau, a protein associated with neurodegenerative diseases, thereby normalizing aberrant disease processes. This approach aims to enhance patient outcomes in areas with significant unmet medical needs, particularly in maintaining brain health.